Oncimmune Holdings plc (ONC) Ordinary 1p
Oncimmune Holdings Plc is a cancer diagnosis company. The Company is engaged in developing and commercializing its EarlyCDT platform technology. Its geographical segments include United Kingdom, North America and Rest of the world. It is engaged in the development of autoantibody tests that can be applied to a range of solid tumor types. EarlyCDT-Lung is a blood test, which is ordered by a doctor to aid in the risk assessment and early detection of lung cancer in high-risk patients and to stratify indeterminate pulmonary nodules for the risk of malignancy. EarlyCDT-Lung test is being used in the randomized trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) Scotland Early Childhood Longitudinal Study (ECLS) of over 12,000 high-risk smokers. It is also developing the EarlyCDT tests for other cancers, which include in particular the liver and ovarian cancers. It has sold over 145,000 tests in the United States and the United Kingdom.